SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new development or finding in product specification without further noticed.
Chemical Name: (E)-2-Cyano-3-morpholinoacrylamide
Shipping Temperature: Ambient
HSN Code: 38229010
Country of Origin: India
Smiles: NC(/C(C#N)=C/N1CCOCC1)=O
Abacavir Impurity 11 is chemically (E)-2-Cyano-3-morpholinoacrylamide. Abacavir Impurity 11 is supplied with detailed characterization data compliant with regulatory guideline. Abacavir Impurity 11 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Abacavir.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Stability indicating RP-HPLC method development and validation for determination of abacavir sulphate in tablet dosage form
By Ithape, Aniket B.; Deshpande, Padmanabh B.; Shelke, Priyanka
From International Journal of Pharmacy and Pharmaceutical Research (2020), 17(4), 670-680
A new stability indicating method was developed and validated for the simultaneous estimation of Lamivudine and Abacavir in tablet dosage form by RP-HPLC
By Rajamahanti, Santoshi G.; Annapurna, N.; Santosh, T.; Durga, B.; Raziya, S. K.
From Research Journal of Pharmaceutical, Biological and Chemical Sciences (2017), 8(3), 407-421
A validated stability-indicating RP-HPLC method for abacavir sulfate in the presence of degradation products, its process-related impurities and identification of oxidative degradant by LC-MS/MS
By Ragham, Pramod Kumar; Chandrasekhar, Kothapalli B.; Reddy, J. Rudraprasad; Kasturi, Krishna Mohan
From Indo American Journal of Pharmaceutical Research (2015), 5(1), 463-473